NRG announces £16m Series A for IND for Parkinson’s and ALS
pharmaphorum
NOVEMBER 9, 2022
If these mitochondrial therapeutics were to be successful in clinical trials, they would be the first disease-modifying medicine to actually prevent or delay progression of these diseases. In ALS , the protein TDP-43 triggers neuroinflammation via activation of the innate immune sensor STING.
Let's personalize your content